CARB-X funds VenatoRx Pharmaceuticals to support the development of a new class of oral antibiotics to treat multi-drug-resistant gonorrhea

CARB-X funds VenatoRx Pharmaceuticals to support the development of a new class of oral antibiotics to treat multi-drug-resistant gonorrhea
Funding represents 51st CARB-X Award, and 2nd CARB-X Award for VenatoRx 

See more here

Comments are closed.